Drugs / ERAS-007
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04959981 | Sep 2021 → Apr 2023 | non-small cell lung carcinoma | Erasca, Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05279859 | Mar 2022 → Mar 2025 | acute myeloid leukemia | Erasca, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT05039177 | Sep 2021 → Aug 2025 | colorectal cancer, pancreatic ductal adenocarcinoma | Erasca, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04866134 | May 2021 → Jul 2026 | — | Erasca, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2024-05-16 | Erasca, Inc. | Results Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise erasca.com ↗
HERKULES-3: ERAS-007 + EC in EC-naïve patients with BRAFm CRC: Deprioritized as clinical efficacy data (data to be presented at ASCO 2024) do not support continued evaluation |
| 2023-06-05 | Erasca, Inc. | Results Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline erasca.com ↗
ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with BRAFm CRC showed a 50% (3/6) response rate (2 cPR, 1 uPR), reinforcing ERAS-007 as a potential best-in-class ERK inhibitor |
| 2023-05-25 | Erasca, Inc. | Results Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting erasca.com ↗
Triplet of ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with metastatic BRAF V600E-mutated colorectal cancer (CRC) showed a 40% (2/5) response rate; |
| 2022-10-12 | Erasca, Inc. | Results Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium erasca.com ↗
Initial Phase 1/1b patient data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in advanced solid tumors show safe and tolerable profiles for combination development |
| 2022-09-07 | Erasca, Inc. | Results Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials erasca.com ↗
today announced promising preliminary Phase 1/1b monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in BRAF-driven and RAS/MAPK-altered solid tumors. |
All press releases naming this drug 16 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERAS-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04959981 ↗ |
| Action | Inhibit | “ERK Inhibitor” NCT04866134 ↗ |
| Route | Oral | “ERAS-007 will be administered orally” NCT04866134 ↗ |